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The TTTT B Lymphocyte Stimulator Promoter Haplotype Is
Associated With Good Response to Rituximab Therapy in
Seropositive Rheumatoid Arthritis Resistant to
Tumor Necrosis Factor Blockers
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Objective. To investigate the polymorphisms in
the promoter region of the B lymphocyte stimulator
(BLyS) gene as markers of response to rituximab (RTX)
in rheumatoid arthritis (RA).
Methods. The study was first conducted in 152
Italian RA patients and then replicated in an additional
117 RA patients (73 Italian, 44 British). The European
League Against Rheumatism response criteria were
used to evaluate the response rate at months 4 and 6
after the first cycle of RTX, by means of the Disease
Activity Score in 28 joints using the erythrocyte sedi-
mentation rate; patients were classified according to the
best response shown between months 4 and 6. BLyS
promoter polymorphisms were analyzed by polymerase
chain reaction followed by the analysis of the restriction
fragments, BLyS promoter haplotypes were analyzed
using the expectation-maximization algorithm, and
BLyS serum levels were analyzed using enzyme-linked
immunosorbent assay. Odds ratios (ORs) were calcu-
lated with 95% confidence intervals (95% CIs).
Results. The TTTT BLyS promoter haplotype
appeared to be significantly associated with response to
RTX only in the subset of seropositive patients (those
positive for rheumatoid factor and/or anti–cyclic citrul-
linated peptide). The replication study confirmed that
this association was limited to seropositive RA patients
in whom treatment with anti–tumor necrosis factor
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(anti-TNF) agents had previously failed. In the whole
series of seropositive patients in whom anti-TNF agents
had previously failed, patients carrying the TTTT BLyS
promoter haplotype were more prevalent in good re-
sponders (18 of 43 [41.9%]) than in moderate respond-
ers (20 of 83 [24.1%]) or in nonresponders (1 of 21
[4.8%]) (for good responders versus nonresponders, OR
14.4 [95% CI 1.77–117.39], P  0.0028). Furthermore,
multivariate analysis selected the TTTT BLyS promoter
haplotype as an independent marker of good response
to RTX (for good responders versus nonresponders, OR
16.2 [95% CI 1.7–152.5], P  0.01; for good responders
versus moderate responders and nonresponders com-
bined, OR 3.1 [95% CI 1.2–7.8], P  0.02). The rela-
tionship between BLyS polymorphisms and BLyS serum
levels remained unclear.
Conclusion. BLyS promoter genotyping may be
suitable for identifying seropositive RA patients who
may have a good response to RTX after anti-TNF agents
have failed.
Rituximab (RTX), a chimeric monoclonal anti-
body directed at the CD20 membrane protein present on
B cells (1), is an effective treatment for patients with
rheumatoid arthritis (RA), especially those positive for
rheumatoid factor (RF) and/or anti–cyclic citrullinated
peptide (anti-CCP) antibodies (2–5). Several studies
demonstrated its efficacy for the treatment of RA,
including RA unresponsive to anti–tumor necrosis factor
(anti-TNF) therapy, underlying the important role of B
cells in this disease (6–10). However, among RA pa-
tients who respond to RTX, some have relapse of their
disease while others show a prolonged response for a
very long time, independently of the reappearance of B
cells in the peripheral blood (usually after 6–8 months)
(9). One possible explanation may reside in the differ-
ential effects of RTX in depleting B cells and blocking
plasma cell generation at the synovial and bone marrow
levels, as recently demonstrated (11–13). However, the
degree and duration of response to RTX may also
depend on individual genetic predisposition.
B lymphocyte stimulator (BLyS), also called
BAFF, is a key cytokine in B cell survival and prolifer-
ation (14), and elevated serum and tissue levels were
described in several autoimmune diseases, including RA
(15,16). The link between BLyS serum levels and BLyS
genetics has been investigated more rarely in rheumatic
diseases, mainly by analyzing the polymorphism
–871C/T in the BLyS promoter region. The –871T allele
was associated with higher BLyS serum levels, but
reported data are limited and patient selection not well
specified (17–19). Of note, BLyS levels further increase
soon after RTX infusion (20,21), possibly contributing
to the reappearance of B cells and affecting the duration
and degree of RTX response. Thus, the regulation of
BLyS expression may be linked to the efficacy of RTX.
In this work we extended an initial study of the
–871C/T BLyS polymorphism (22) to all the common
polymorphisms located in the 5 regulatory region of the
BLyS gene, which are in strong linkage disequilibrium
and form 4 major haplotypes (23). The study was first
conducted in a large retrospective cohort of Italian RA
patients treated with RTX. Response rates were ana-
lyzed both at month 4 and at month 6 after RTX
treatment, and the best response shown between months
4 and 6 was chosen to identify 3 response subgroups:
good responders, moderate responders, and nonre-
sponders. In addition, we considered 3 established items
related to response to RTX (RF positivity, anti-CCP
positivity, and previous anti-TNF therapy [2]) to better
dissect the possible predictive role of the genetic data in
different subgroups of RA patients. Finally, a replication
study was conducted in an additional 117 unselected RA
patients. The possible correlation between BLyS genet-
ics and BLyS serum levels was also investigated.
PATIENTS AND METHODS
Study populations. The study was first conducted in a
retrospective cohort of 152 unselected RA patients who had
been referred to 6 rheumatology centers in Italy. The replica-
tion series comprised 117 additional, unselected RA patients,
73 of whom were referred to 7 different Italian rheumatology
centers, and 44 of whom were British patients followed up at
the University of Leeds. All RA patients were diagnosed
according to the 1987 American College of Rheumatology
revised classification criteria (24). All patients gave their
informed consent to participation in the study, in accordance
with the Declaration of Helsinki, and the investigation was
approved by the local study review boards.
Demographic and clinical features of the study patients
are illustrated in Table 1. Patients included in these 2 series
represent the large majority of RA patients treated with RTX
in those centers, and all of them were followed up for at least 6
months after RTX treatment. All patients were taking10 mg/
day of prednisone or equivalent, and no increase in the cor-
ticosteroid dosage was allowed after RTX therapy was begun.
All patients were treated with intravenous infusions of RTX
(500 mg at weeks 0, 1, and 2 or 1,000 mg at weeks 0 and 2)
either as monotherapy (4.1%) or in combination with either
methotrexate (MTX) or other disease-modifying antirheu-
matic drugs (DMARDs), such as leflunomide, cyclosporin A,
or hydroxychloroquine (95.9%). In the majority of patients,
treatment with 1 or more anti-TNF agents had failed due to
primary or secondary inefficacy. In the remaining patients, the
disease was unresponsive to at least 6 months of treatment with
MTX alone or in combination with other DMARDs with RTX
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representing the first biologic therapy. RA patients in whom
anti-TNF therapy had failed only because of side effects were
excluded from the study.
The European League Against Rheumatism (EULAR)
response criteria (25) were used to evaluate response rates at
months 4 and 6 after the first cycle of RTX, by means of the
Disease Activity Score in 28 joints (26) using the erythrocyte
sedimentation rate (DAS28-ESR). Patients were finally classi-
fied according to their best response between months 4 and 6
after RTX treatment, since this proved to be more relevant
than the single evaluation of response at either month 4 or
month 6 to determine whether to proceed with RTX retreat-
ment (9).
BLyS promoter genotyping. DNA was extracted from
EDTA-treated peripheral blood using an automated method
(Maxwell 16; Promega) and dedicated kits (Maxwell 16 Blood
DNA purification kit). The single-nucleotide polymorphism
(SNP) –871 CT (rs9514828) was first analyzed following
previously reported methods (19). Then, according to the
method used by Nossent et al (23), the other 3 SNPs in the
haplotype block of the 5-regulatory region of the BLyS gene
were also analyzed: –2841 TC (rs9514827), –2704 TC
(rs3759467), and –2701 TA (rs1041569). The analyses of the
–2841 TC (rs9514827), –2704 TC (rs3759467), and –2701
TA (rs1041569) polymorphisms were made starting from the
same amplicon. All polymerase chain reaction products were
digested with 10 units of the appropriate restriction enzyme for
at least 2 hours at the temperature recommended by the
manufacturer. The restriction fragments were run onto 2%
ethidium bromide–stained agarose gels with sodium borate
buffer and visualized with a Phosphor Imager (Bio-Rad).
Enzyme-linked immunosorbent assay (ELISA) for
BLyS serum level analysis. BLyS serum levels were analyzed
by ELISA using commercially available kits (Quantikine Hu-
man BAFF/BLyS, lower limit of detection 3.38 pg/ml; R&D
Systems). Baseline sera were available only from a fraction of
RA patients under study (n  82).
Statistical analysis. BLyS haplotypes, defined by the
4 above mentioned SNPs in the promoter region, were ana-
lyzed using the freely available hapassoc software, version 1.1
(Simon Fraser University, Burnaby, British Columbia, Can-
ada), which estimates haplotypes using the expectation-
maximization algorithm, as indicated by Nossent et al (23). The
chi-square test or Fisher’s exact test for categorical variables
and the Mann-Whitney test for quantitative variables were
used, after verifying the assumptions, for univariate analysis.
Multivariate analysis was performed by stepwise logistic re-
gression, where age, sex, baseline DAS28-ESR, RF status, anti-
CCP status, failure of anti-TNF therapy, and BLyS haplotypes
were chosen as covariates to be included in the model to assess
the variables predicting EULAR response. All these variables
were available in all cases. Odds ratios (ORs) are provided
with 95% confidence intervals (95% CIs). Data were analyzed
with SPSS software, version 15.1. P values less than or equal to
0.05 were considered significant.
RESULTS
Response to RTX and genetic studies in the first
study population. The first study population comprised
152 RA patients treated with RTX who presented a high
prevalence of seropositivity (86.8% RF positive and/or
anti-CCP positive) and a large majority of whom had a
history of anti-TNF therapy failure (73.7%). According
to the evaluation of the best clinical response between
month 4 and month 6, 3 subgroups were identified: good
Table 1. Baseline characteristics of the study patients*
First series of patients
(n  152)
Replication series of patients
(n  117)
Demographics
Female 127 (83.6) 102 (87.2)
Age, mean  SD (range) years 61 13 (23–84) 57  12 (29–84)
Disease status
RF positive 123 (80.9)† 81 (69.2)
Anti-CCP positive 120 (78.9)‡ 82 (70.1)
RF positive and/or anti-CCP positive 132 (86.8) 97 (82.9)
DAS28-ESR, mean  SD (range) 5.91  1.11 (3.10–8.38) 5.85 1.31 (2.68–8.52)
Disease duration, mean  SD (range) years 12.3 9.5 (1–44) 15.5 11.4 (1–56)
Medications
Concomitant DMARDs 149 (98) 109 (93.4)
Concomitant MTX 127 (83.6) 96 (82.1)
Anti-TNF naive 40 (26.3)§ 50 (42.7)
Number of biologic agents before RTX,
mean  SD (range)
1.5  0.7 (1–4) 1.7 0.6 (1–3)
* Except where indicated otherwise, values are the number (%). RF  rheumatoid factor; anti-CCP  anti–cyclic
citrullinated peptide; DAS28-ESR  Disease Activity Score in 28 joints using the erythrocyte sedimentation rate;
DMARDs  disease-modifying antirheumatic drugs; MTX  methotrexate; anti-TNF  anti–tumor necrosis factor;
RTX  rituximab.
† Odds ratio (OR) 1.81 (95% confidence interval [95% CI] 1.03–3.19), P  0.0437 versus replication series of patients.
‡ OR 1.61 (95% CI 0.92–2.79), P  0.12 versus replication series of patients.
§ OR 2.09 (95% CI 1.25–3.50), P  0.0061 versus replication series of patients.
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responders (51/152, 33.6%), moderate responders (78/
152, 51.3%), and nonresponders (23/152, 15.1%). After
RTX therapy, 1% of CD19 B cells were depleted
between months 1 and 3 in all patients. Neither the
baseline CD19 B cell count nor their relative depletion
appeared significantly related to the degree of response
(data not shown).
As expected from previous studies (2–4), RF-
positive and/or anti-CCP–positive antibody status and
naive anti-TNF agent status (no previous therapies with
anti-TNF agents before RTX) were significantly associ-
ated with a positive (good or moderate versus no
response) response to RTX (Figure 1). In particular, the
highest percentage of good responders (18/40, 45%) and
the lowest percentage of nonresponders (2/40, 5%) were
among the anti-TNF–naive patients. No difference in
the response rate was noted between patients treated
with RTX plus DMARDs and patients treated with
RTX alone (data not shown).
The study of the possible influence of BLyS
genetic variants on the response to RTX started with the
analysis of the prevalence of the –871 CT BLyS
promoter polymorphism. The prevalence of the –871
CT polymorphism genotypes (CC 23.7%, CT 53.3%,
TT 23%) appeared comparable to that previously re-
ported in other RA patient series and in Caucasian
controls (17–19,23). As illustrated in Table 2, there was
no clear association between the –871 CT BLyS poly-
morphism and response to RTX; in particular, the rate
of response in homozygous CC and TT patients ap-
peared very similar and differed from that in the
heterozygous (CT) patients, where the highest preva-
lence of nonresponders was found.
The analysis of the other BLyS promoter poly-
morphisms was then performed. The 5 regulatory re-
gion of the human BLyS gene presents the following 4
polymorphic sites: –2841 TC (rs9514827), –2704 TC
(rs3759467), –2701 TA (rs1041569), and the best stud-
ied –871 CT. The 4 SNPs are in strong linkage
disequilibrium and form 4 common (frequency 5%)
haplotypes: CTAT, TTAC, TTTT, and TCAC. In this
first series of RA patients, the cumulative frequencies of
the estimated BLyS haplotypes (CTAT 0.283, TTAC
0.270, TTTT 0.168, TCAC 0.161, rare pool 0.119) were
Figure 1. Clinical variables associated with response to rituximab in the first study population. Rheumatoid factor (RF)–positive patients showed
a higher response rate than did RF-negative patients. For good responders and moderate responders combined versus nonresponders (NR),  
odds ratio (OR) 15.4 (95% confidence interval [95% CI] 5.54–42.80), P  0.0001. Anti–cyclic citrullinated peptide (anti-CCP)–positive patients
showed a higher response rate than did anti-CCP–negative patients. For good responders and moderate responders combined versus nonresponders,
  OR 3.74 (95% CI 1.46–9.61), P  0.0098. Anti–tumor necrosis factor (anti-TNF)–naive patients showed a higher response rate than did
patients in whom anti-TNF agents had failed. For good responders and moderate responders combined versus nonresponders,   OR 4.39 (95%
CI 0.98–19.64), P  0.041.
Table 2. Prevalence of BLyS genotypes (871 CT polymorphism)
in the 3 subgroups of response to RTX in the first series of patients
(n  152)*
Best response to RTX
between months 4 and 6
of treatment (n)
BLyS 871
genotypes
CC
(n  36)
CT
(n  81)
TT
(n  35)
Good (51) 11 (30.6) 28 (34.6) 12 (34.3)
Moderate (78) 22 (61.1) 34 (42.0) 22 (62.9)
No response (23) 3 (8.3) 19 (23.5) 1 (2.9)
* Values are the number (%). BLyS  B lymphocyte stimulator;
RTX  rituximab.
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consistent with those reported by the HapMap project
(www.hapmap.org) and observed by Nossent et al (23).
The prevalence of BLyS haplotypes did not differ sig-
nificantly between RF-positive and RF-negative patients
or between anti-CCP–positive and anti-CCP–negative
patients (data not shown).
When related to the response to RTX (Table 3),
the prevalence of the TTTT haplotype gradually de-
creased, from 0.206 in good responders to 0.167 in
moderate responders and to 0.087 in nonresponders.
More patients carrying the TTTT haplotype were good
responders (19 of 51 [37.3%]) than were moderate
responders (22 of 78 [28.2%]) or were nonresponders
(3 of 23 [13%]) (for good responders versus nonre-
sponders, OR 3.96 [95% CI 1.04–15.12], P  0.05). No
significance was found for the remainder of the compar-
isons. An association of the other major haplotypes with
response to RTX was not found, while the rare haplo-
types were more prevalent among the nonresponders
(the TTTC haplotype in particular, with 0.109 in non-
responders versus 0.064 in moderate responders versus
0.039 in good responders; P not significant [NS]).
We then investigated the link between BLyS
haplotypes and response to RTX by distinguishing be-
tween seropositive and seronegative RA patients. In
fact, the presence of RF and anti-CCP antibodies is a
well-established predictor of response to RTX (2–4),
and seropositivity versus seronegativity characterizes
different subsets of RA based on genetic studies (27–
33). Of note, the association between the presence of the
TTTT haplotype (either in homozygosis or in heterozy-
gosis) and response to RTX was significant only in the
seropositive subset and when comparing good response
with absence of response, excluding moderate respond-
ers. Of seropositive patients carrying at least 1 TTTT
haplotype, 18 of 49 (36.7%) were good responders, 21 of
70 (30%) were moderate responders, and 1 of 13 (7.7%)
were nonresponders (for good responders versus non-
responders, OR 6.97 [95% CI 0.84–58.14], P  0.050).
The remainder of the comparisons were not significant.
In contrast, no association between BLyS haplo-
types and response to RTX was noted in the subset of
seronegative RA patients, where good responders (2
patients) and moderate responders (8 patients) were
grouped together and compared with nonresponders (10
patients) due to the limited number of patients. Also,
the study of the single –871 BLyS polymorphism did not
reveal a significant association in this subset, although a
higher rate of response (good or moderate) was ob-
served in CC patients than in CT/TT patients (5 of 6
[83.3%] versus 5 of 14 [35.7%]) (OR 9 [95% CI 0.81–
100.20], P  0.14). Thus, BLyS genetic variants may be
differently associated with response to RTX in seropos-
itive compared to seronegative RA.
In seropositive RA patients, a further subanalysis
was done distinguishing between patients who did and
patients who did not receive anti-TNF therapies before
receiving RTX (2). In seropositive patients in whom
anti-TNF therapy had failed, the TTTT haplotype was
present only in responders. In fact, 10 of 31 TTTT
carriers were good responders (32.3%), 13 of 52 were
moderate responders (25%), and 0 of 11 were nonre-
sponders (0%) (for good responders versus nonre-
sponders, OR 11.2 [95% CI 0.60–209.67], P 0.04). The
remainder of the comparisons were not significant.
Thus, the presence of at least 1 TTTT haplotype in
seropositive RA patients in whom anti-TNF agents had
failed was associated with a good response to RTX
rather than an absence of response. In contrast, since
seropositive RA patients receiving RTX as first-line
therapy did not respond to RTX very rarely (2 of 38
Table 3. Prevalence of BLyS promoter haplotypes in the 3 subgroups of response to RTX in the first
series of patients (n  152)*
Best response to RTX
between months 4 and 6
of treatment (n)
BLyS promoter haplotypes†
CTAT TTAC TTTT TCAC Rare pool
Good (51) 0.275 0.255 0.206 0.176 0.088
Moderate (78) 0.269 0.282 0.167 0.147 0.135
No response (23) 0.348 0.261 0.087 0.152 0.152
* The cumulative prevalence of each haplotype is indicated for each subgroup of response to RTX. The
prevalence of the TTTT haplotype was greater in good responders than in nonresponders, although the
difference was not significant (P  0.097). See Table 2 for definitions.
† Haplotypes were composed following this order: 2841 TC (rs9514827), 2704 TC (rs3759467),
2701 TA (rs1041569), and 871 CT (rs9514828).
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[5.3%]), a statistical evaluation of BLyS genetics as a
predictor of response to RTX could not be performed.
Replication study. The replication study was con-
ducted in 117 RA patients from 8 independent rheuma-
tology centers (7 in Italy, 1 in the UK). The demographic
and clinical features of these patients are illustrated in
Table 1. The patients in the replication study were
comparable to those in the first study population in
terms of age, sex, disease duration, and baseline disease
activity (mean  SD DAS28-ESR 5.85  1.31 versus
5.91  1.11, respectively; P NS). As illustrated in Table
1, the percentages of seropositive patients (RF positive
and/or anti-CCP positive) were comparable (82.9% in
the replication study versus 86.8% in the first study
population; P NS), although fewer patients in the repli-
cation study were RF positive (69.2% versus 80.9%; OR
1.81 [95% CI 1.03–3.19], P  0.0437). Of note, more
patients in the replication study were anti-TNF naive
(50 of 117 [42.7%] versus 40 of 152 [26.3%]; OR 2.09
[95% CI 1.25–3.50], P  0.0061).
The overall rate of response to RTX was compa-
rable to that found in the first study patients (32 of 117
good responders [27.4%], 58 of 117 moderate respond-
ers [49.6%], and 27 of 117 nonresponders [23.1%]).
Seropositive (RF positive and/or anti-CCP positive)
patients again showed a higher response than seroneg-
ative patients (82 of 97 [84.5%] versus 8 of 20 [40%]; OR
14.35 [95% CI 5.37–38.36], P  0.0001), and anti-TNF–
naive patients tended to respond better (82%) than
patients in whom anti-TNF therapy had failed (73.1%)
(P NS).
The genotypic prevalence of the –871 CT BLyS
polymorphism was similar in both the first and replica-
tion populations. Again, no association was found be-
tween the –871 BLyS polymorphism and response to
RTX (data not shown).
BLyS haplotypes were then investigated in sero-
positive RA patients, and we distinguished patients in
whom anti-TNF agents had failed from patients who
were anti-TNF naive. The association between the
TTTT haplotype and good response to RTX was con-
firmed in seropositive RA patients in whom anti-TNF
agents had failed, since good responders to RTX showed
the highest TTTT cumulative frequencies (0.375 in good
responders versus 0.145 in moderate responders versus
0.050 in nonresponders) and the highest percentage of
patients carrying at least 1 TTTT haplotype (8 of 12
[66.7%] in good responders versus 7 of 21 [33.3%] in
moderate responders versus 1 of 10 [10%] in nonre-
sponders). Statistical analyses revealed the highest sig-
nificant difference when comparing good responders
with nonresponders (for good responders versus nonre-
sponders, OR 18 [95% CI 1.65–196.42], P 0.01 and for
good responders versus moderate responders and non-
responders combined, OR 5.75 [95% CI 1.36–24.40],
P  0.03). The remainder of the comparisons were not
significant. Thus, as in the first study population, the
presence of the TTTT haplotype in seropositive RA
patients in whom anti-TNF agents had failed was signif-
icantly associated with a good response to RTX. Again,
no significant association was found between the BLyS
haplotypes and response to RTX in seropositive anti-
TNF–naive patients or in seronegative RA patients
(data not shown).
Finally, the –871 CC genotype tended to be more
prevalent in seronegative RA patients who responded to
RTX (good/moderate response in 4 of 9 CC patients
[44.4%] versus 4 of 11 CT/TT patients [36.4%]; P NS)
also in the replication study.
Results by grouping the first series of patients
with the replication series. In the whole series of 147
seropositive RA patients in whom anti-TNF therapy had
failed (94 in the first series plus 53 in the replication
series), the association between the TTTT BLyS haplo-
type and good response to RTX reached a higher
statistical significance (Figure 2A). The TTTT cumula-
tive frequency was 24.4% in good responders versus
4.59% in moderate responders and 2.49% in nonre-
sponders (for good/moderate responders versus nonre-
sponders, OR 8.6 [95% CI 1.15–64.27], P  0.0094 and
for good responders versus nonresponders, OR 12.37
[95% CI 1.59–96.00], P  0.0018) (Figure 2A). Patients
carrying at least 1 TTTT haplotype were more prevalent
among good responders than among moderate respond-
ers (18 of 43 [41.9%] versus 20 of 83 [24.1%]; OR 2.27
[95% CI 1.03–4.99], P 0.044) or among nonresponders
(18 of 43 [41.9%] versus 1 of 21 [4.8%]; OR 14.4 [95%
CI 1.77–117.39], P  0.0028). Even if the number of
cases was limited, no significant association was found
between BLyS polymorphisms and response to RTX in
the whole series of anti-TNF–naive seropositive patients
(Figure 2B).
In the seronegative RA patients overall, no sig-
nificant association was found between BLyS haplotypes
and response to RTX. However, a trend was observed
for the –871 CT BLyS polymorphism (good/moderate
response in 9 of 15 –871 CC patients [60%] versus 9 of
25 –871 CT/TT patients [36%]; OR 2.67 [95% CI
0.71–9.95], P  0.19).
Notably, the disease duration did not influence
the rate of EULAR responses (median [range] 12 years
[2–40 years] for no EULAR response versus 10.5 years
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[1–56 years] for EULAR moderate response versus 10
years [1–43 years] for EULAR good response; P  0.68
by Kruskal-Wallis test). Also, the mean  SD baseline
DAS28-ESR was not different among the 3 EULAR
response categories (5.6  1.2 for no EULAR response
versus 5.9  1.2 for EULAR moderate response versus
6.1  1.1 for EULAR good response; P  0.08 by
analysis of variance), and the absence of significant
differences among EULAR response categories was also
observed for the number of TNF blockers that had
previously failed (median [range] 1 [0–4] for no EULAR
response versus 1 [0–4] for EULAR moderate response
versus 1 [0–3] for EULAR good response; P  0.2 by
Kruskal-Wallis test).
Results of multivariate statistical analyses.
Based on the univariate results, multivariate analyses
were performed, using logistic regression analyses in 3
different models, in seropositive RA patients in whom
anti-TNF therapy had failed. In the first model, the
dependent variable was the presence of a EULAR good
response (as the best response between months 4 to 6
after RTX treatment) versus the absence of response;
in the second model, the dependent variable was a
EULAR good response versus a EULAR moderate
response or the absence of response; and, in the third
model, the dependent variable was the presence of a
EULAR good or moderate response versus the absence
of response. Age, sex, baseline Health Assessment Ques-
tionnaire (34) score, baseline DAS28-ESR, previous
anti-TNF therapy, and the presence of the TTTT BLyS
promoter haplotype were introduced as covariates. Of
note, the association of the TTTT BLyS haplotype with
response to RTX was significant only in the first and
second models (OR 16.2 [95% CI 1.7–152.5], P  0.01
and OR 3.1 [95% CI 1.2–7.8], P  0.02, respectively; P
NS in the third model). Thus, the association of the
TTTT BLyS haplotype with a good response to RTX,
rather than with a moderate response, was again high-
lighted. Conversely, in patients not carrying the TTTT
haplotype, there was a higher risk of no response
(Figure 3).
Possible relationship between BLyS serum levels
and genetic variants. Sera collected before RTX therapy
were available from 82 RA patients, and BLyS serum
levels appeared significantly more elevated in RA pa-
tients than in controls (mean  SD 1,102  484 pg/ml
versus 655  158 pg/ml; P  0.0001). Increased BLyS
Figure 2. The TTTT B lymphocyte stimulator (BLyS) haplotype is associated with response to rituximab (RTX) in seropositive patients in whom
anti-TNF agents have failed. A and B, The cumulative prevalence of the TTTT haplotype among all BLyS haplotypes (open bars) and the percentage
of patients carrying the TTTT haplotype (both in heterozygosis and in homozygosis) (solid bars) are represented in the 3 subgroups of response to
RTX, both in patients in whom anti-TNF agents have failed (A) and in anti-TNF–naive patients (B). A, In patients in whom anti-TNF agents had
failed, the TTTT BLyS haplotype was more prevalent in good responders than in moderate responders or in nonresponders. For good responders
versus nonresponders,   OR 14.4 (95% CI 1.77–117.39), P  0.0028. B, No clear association was found in anti-TNF–naive patients. The other
BLyS haplotypes are not illustrated since they did not change significantly among the different classes of response to RTX. See Figure 1 for other
definitions.
Figure 3. Pie charts showing different patterns of European League
Against Rheumatism (EULAR) response in the pooled series of
seropositive rheumatoid arthritis patients in whom anti–tumor necro-
sis factor agents had failed. Left, Pattern of EULAR response in
patients not carrying at least 1 TTTT haplotype (0). Right, Pattern of
EULAR response in patients carrying at least 1 TTTT haplotype (1).
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levels (i.e., 939 pg/ml, which represents the 95th
percentile, such as the upper cutoff of the physiologic
range) were found in 42 of 82 patients (51.2%). In RA,
BLyS levels did not correlate significantly with age, but
appeared significantly more elevated in females than in
males (709  161 pg/ml versus 611  144 pg/ml; P 
0.0196). BLyS serum levels were similar in seropositive
and seronegative RA (1,083  468 pg/ml versus 1,149 
531 pg/ml; P  0.64) and similar in patients in whom
anti-TNF agents had failed as compared to anti-TNF–
naive patients (1,077  466 pg/ml versus 1,181  564
pg/ml; P  0.33). In contrast to previous data (22), the
different –871 CT BLyS genotypes were not associated
with significantly different BLyS serum levels (1,038 
506 pg/ml for CC, 1,161 511 pg/ml for CT, 1,007 266
pg/ml for TT; P NS).
Among the seropositive RA patients in whom
anti-TNF agents had failed, good responders to RTX
tended to have lower baseline BLyS levels than moder-
ate responders, who in turn tended to have lower
baseline BLyS levels than nonresponders, but the differ-
ence was not significant (895  174 pg/ml, 967  236
pg/ml, and 1,199  594 pg/ml, respectively; P  0.38 for
good responders versus nonresponders). In the same
subgroup of patients, BLyS levels in TTTT carriers
(977  194 pg/ml) did not differ compared to those in
non–TTTT carriers (1,011  404 pg/ml). Considering
the subset of seronegative RA patients, the –871 CC
patients tended to show higher BLyS serum levels than
the CT/TT patients (1,341  730 pg/ml versus 1,026 
328 pg/ml; P  0.24), but responder patients did not
have higher BLyS serum levels than nonresponder pa-
tients (1,138  471 pg/ml versus 1,156  583 pg/ml; P
NS). In conclusion, a significant relationship between
BLyS polymorphisms and BLyS serum levels was not
found in this study.
DISCUSSION
In the present study, we investigated the associ-
ation between BLyS genetics and response to RTX in
RA, extending for the first time in RA, the genetic study
to all the 4 common polymorphisms located in the BLyS
promoter (23). We found a significant association be-
tween BLyS genetics and good, rather than moderate,
response to RTX. The results were confirmed by repli-
cation studies. In a first series of 152 RA patients, we
found a significant association between the TTTT BLyS
haplotype and a good response to RTX, and this asso-
ciation was limited to seropositive RA patients in whom
anti-TNF therapy had previously failed. Data were then
confirmed in a second independent series of 117 RA
patients, and pooled analyses on the overall cases
showed an even stronger relationship between a good
response to RTX and the TTTT BLyS haplotype.
The list of biologic agents for RA is rapidly
growing, and the identification of genetic biomarkers
able to predict response to therapy is a relevant issue
(27). However, previous data in the literature were often
preliminary and replications were frequently lacking or
had conflicting results. Moreover, different subsets of
patients were not analyzed in detail. In the present
study, the replication series was fundamental to confirm-
ing the TTTT BLyS haplotype as a specific marker of
good response to RTX in a definite subgroup of RA
patients.
Although RTX may prove effective as first-line
biologic therapy (28), as was also observed in the present
study, this drug is licensed for use only after the failure
of anti-TNF agents in RA. Second, RTX is recom-
mended more often in autoantibody-positive RA pa-
tients. Third, a good response to therapy, rather than a
moderate response, is currently the main goal of any
biologic therapy in RA (29). Thus, the TTTT BLyS
haplotype, the reported genetic marker associated with a
good response to RTX in seropositive RA patients in
whom anti-TNF therapy has previously failed (2), is of
clinical relevance.
The response to anti-TNF therapy may be a tool
by which to identify a subset of RA in which TNF may be
relevant for treatment of chronic synovitis (30). Based
on the present results, the failure of anti-TNF therapy
may also highlight a subset of RA in which B cells may
be more implicated and in which BLyS genetic studies
are more helpful.
In addition, the present study compared seropos-
itive (RF-positive and/or anti-CCP–positive) RA pa-
tients (n  229), who are widely recognized as the best
responders to RTX (2–5), to seronegative RA patients
(n  40). Although the number of seronegative patients
was limited, our findings suggest a different role of BLyS
genetics as a biomarker in either seropositive or sero-
negative RA, similar to other genetic biomarkers (31–
33,35–38).
BLyS favors B cell survival and proliferation (14),
is overexpressed in RA synovium (39,40), and is in-
creased after RTX therapy (20,21), and this might favor
resistance to RTX (41,42). The association of BLyS
genetics with response to RTX may be linked to a role
of BLyS in sustaining the proliferation of autoimmune
B cell clones, autoantibody secretion, and chronic RA
synovitis before and/or after RTX therapy.
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In the present investigation, the –871 CT BLyS
polymorphism was not confirmed as a suitable genetic
marker for predicting response to RTX in the overall
RA population, in contrast to preliminary data in a
smaller series (22). However, the possible usefulness of
the –871 CT BLyS polymorphism in seronegative RA
may need further investigation.
Neither the study of the –871 CT BLyS poly-
morphism nor the study of the complete BLyS promoter
haplotype was sufficient to identify a significant relation-
ship between BLyS serum levels and BLyS genetic
variants in RA in the present study. One possible
explanation is that the commercial ELISAs used for the
BLyS dosage, including the ELISA used in the present
study, may be insufficient to give a complete picture of
BLyS expression (43,44). Furthermore, membrane ex-
pression of which may differ from serum levels of BLyS,
can be used to infer the presence of RA disease activity
and predict response to RTX. More comprehensive
analyses are then required. Our group has planned
additional studies of the different BLyS isoforms (43,44)
in serum and at the tissue level.
In conclusion, the BLyS promoter haplotype may
represent a useful tool with which to predict a response
to RTX in those RA patients in whom this drug is
currently recommended (i.e., seropositive patients in
whom anti-TNF therapy has failed). Of note, we found
a relationship between BLyS genetics and a good re-
sponse to therapy, which is the current goal of biologic
treatment.
ACKNOWLEDGMENTS
We thank Prof. Lisamaria Bambara, Prof. Francesco
Curcio, and Prof. Maurizio Cutolo for scientific support,
Dr. Paola Masolini for technical contributions, and Dr. Kim
Falzari for English language revision of the manuscript.
AUTHOR CONTRIBUTIONS
All authors were involved in drafting the article or revising it
critically for important intellectual content, and all authors approved
the final version to be published. Dr. De Vita had full access to all of
the data in the study and takes responsibility for the integrity of the
data and the accuracy of the data analysis.
Study conception and design. Fabris, Quartuccio, De Vita.
Acquisition of data. Fabris, Quartuccio, Vital, Pontarini, Salvin,
Fabro, Zabotti, Benucci, Manfredi, Ravagnani, Biasi, Atzeni, Sarzi-
Puttini, Morassi, Fischetti, Bazzicchi, Saracco, Pellerito, Cimmino,
Carraro, Semeraro, Schiavon, Caporali, Bortolotti, Govoni, Fogolari,
Tonutti, Bombardieri, Emery, De Vita.
Analysis and interpretation of data. Fabris, Quartuccio, Emery,
De Vita.
REFERENCES
1. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab
R, et al. Depletion of B cells in vivo by chimeric mouse human
monoclonal antibody to CD20. Blood 1994;83:435–45.
2. Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M,
et al. Rheumatoid factor positivity rather than anti-CCP positivity,
a lower disability and a lower number of anti-TNF agents failed
are associated with response to rituximab in rheumatoid arthritis.
Rheumatology (Oxford) 2009;48:1557–9.
3. Tak PP, Cohen S, Emery P, Saadeh CK, De Vita S, Donohue JP,
et al. Baseline autoantibody status (RF, anti-CCP) and clinical
response following the first treatment course with rituximab
[abstract]. Arthritis Rheum 2006;54 Suppl:S368–9.
4. Van Vollenhoven RF, Chatzidionysiou K, Gabay C, Hetland ML,
Tarp U, Gomez-Reino JJ, et al. Rheumatoid factor predicts
response to rituximab in a European registry-based cohort:
6-month results from the Collaborative European Registries for
Rituximab in Rheumatoid Arthritis (CERERRA). Ann Rheum
Dis 2009;68 Suppl III:iii579.
5. Pyrpasopoulou A, Douma S, Triantafyllou A, Simoulidou E,
Samara M, Parapanisiou E, et al. Response to rituximab and
timeframe to relapse in rheumatoid arthritis patients: association
with B-cell markers. Mol Diagn Ther 2010;14:43–8.
6. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A,
Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with
rituximab in patients with rheumatoid arthritis. N Engl J Med
2004;350:2572–81.
7. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G.
Efficacy of selective B cell blockade in the treatment of rheuma-
toid arthritis: evidence for a pathogenetic role of B cells. Arthritis
Rheum 2002;46:2029–33.
8. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA,
Genovese MC, et al, for the REFLEX Trial Group. Rituximab for
rheumatoid arthritis refractory to anti–tumor necrosis factor ther-
apy: results of a multicenter, randomized, double-blind, placebo-
controlled, phase III trial evaluating primary efficacy and safety at
twenty-four weeks. Arthritis Rheum 2006;54:2793–806.
9. De Vita S, Quartuccio L. Treatment of rheumatoid arthritis with
rituximab: an update and possible indications. Autoimmun Rev
2006;5:443–8.
10. Finckh A, Ciurea A, Brulhart L, Kyburz D, Moller B, Dehler S, et
al, on behalf of the physicians of the Swiss Quality Management
Program for Rheumatoid Arthritis. B cell depletion may be more
effective than switching to an alternative anti–tumor necrosis
factor agent in rheumatoid arthritis patients with inadequate
response to anti–tumor necrosis factor agents. Arthritis Rheum
2007;56:1417–23.
11. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag
DM, Tak PP. Synovial tissue response to rituximab: mechanism of
action and identification of biomarkers of response. Ann Rheum
Dis 2008;67:917–25.
12. Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D,
Gerlag DM, Tak PP. Early effects of rituximab on the synovial cell
infiltrate in patients with rheumatoid arthritis. Arthritis Rheum
2007;56:772–8.
13. Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M.
Short- and long-term effects of anti-CD20 treatment on B cell
ontogeny in bone marrow of patients with rheumatoid arthritis.
Arthritis Res Ther 2009;11:R123.
14. Treml JF, Hao Y, Stadanlick JE, Cancro MP. The BLyS family:
toward a molecular understanding of B cell homeostasis. Cell
Biochem Biophys 2009;53:1–16.
15. Mackay F, Sierro F, Grey ST, Gordon TP. The BAFF/APRIL
system: an important player in systemic rheumatic diseases. Curr
Dir Autoimmun 2005;8:243–65.
16. Nakajima K, Itoh K, Nagatani K, Okawa-Takatsuji M, Fujii T,
96 FABRIS ET AL
Kuroki H, et al. Expression of BAFF and BAFF-R in the synovial
tissue of patients with rheumatoid arthritis. Scand J Rheumatol
2007;36:365–72.
17. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K.
Analysis on the association of human BLYS (BAFF, TNFSF13B)
polymorphisms with systemic lupus erythematosus and rheuma-
toid arthritis. Genes Immun 2002;3:424–9.
18. Gottenberg JE, Sellam J, Ittah M, Lavie F, Proust A, Zouali H, et
al. No evidence for an association between the -871 T/C promoter
polymorphism in the B-cell-activating factor gene and primary
Sjo¨gren’s syndrome. Arthritis Res Ther 2006;8:R30.
19. Emmerich F, Bal G, Barakat A, Milz J, Muhle C, Martinez-
Gamboa L, et al. High-level serum B-cell activating factor and
promoter polymorphisms in patients with idiopathic thrombocyto-
penic purpura. Br J Haematol 2007;136:309–14.
20. Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone
TS, Teodorescu M, et al. B cell depletion therapy in systemic lupus
erythematosus: relationships among serum B lymphocyte stimula-
tor levels, autoantibody profile and clinical response. Ann Rheum
Dis 2008;67:1011–6.
21. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM,
Edwards JC. Circulating levels of B lymphocyte stimulator in
patients with rheumatoid arthritis following rituximab treatment:
relationships with B cell depletion, circulating antibodies, and
clinical relapse. Arthritis Rheum 2006;54:723–32.
22. Fabris M, Quartuccio L, Saracco M, Pellerito R, Atzeni F,
Sarzi-Puttini P, et al. BLyS promoter polymorphism and response
to rituximab in rheumatoid arthritis (RA) patients positive or
negative for the rheumatoid factor. Ann Rheum Dis 2009;68 Suppl
III:iii75.
23. Nossent JC, Lester S, Zahra D, Mackay CR, Rischmueller M.
Polymorphism in the 5’ regulatory region of the B-lymphocyte
activating factor gene is associated with the Ro/La autoantibody
response and serum BAFF levels in primary Sjo¨gren’s syndrome.
Rheumatology (Oxford) 2008;47:1311–6.
24. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF,
Cooper NS, et al. The American Rheumatism Association 1987
revised criteria for the classification of rheumatoid arthritis.
Arthritis Rheum 1988;31:315–24.
25. Van Gestel AM, Prevoo ML, van ’t Hof MA, van Rijswijk MH, van
de Putte LB, van Riel PL. Development and validation of the
European League Against Rheumatism response criteria for rheu-
matoid arthritis: comparison with the preliminary American Col-
lege of Rheumatology and the World Health Organization/Inter-
national League Against Rheumatism criteria. Arthritis Rheum
1996;39:34–40.
26. Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de
Putte LB, van Riel PL. Modified disease activity scores that
include twenty-eight–joint counts: development and validation in a
prospective longitudinal study of patients with rheumatoid arthri-
tis. Arthritis Rheum 1995;38:44–8.
27. Emery P, Dorner T. Optimising treatment in rheumatoid arthritis:
a review of potential biological markers of response. Ann Rheum
Dis 2011;70:2063–70.
28. Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven
RF, Stohl W, et al. Sustained inhibition of progressive joint
damage with rituximab plus methotrexate in early active rheuma-
toid arthritis: 2-year results from the randomised controlled trial
IMAGE. Ann Rheum Dis 2012;71:351–7.
29. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F,
Dougados M, et al. EULAR recommendations for the manage-
ment of early arthritis: report of a task force of the European
Standing Committee for International Clinical Studies Including
Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34–45.
30. Bugatti S, Manzo A, Bombardieri M, Vitolo B, Humby F, Kelly S,
et al. Synovial tissue heterogeneity and peripheral blood biomark-
ers. Curr Rheumatol Rep 2011;13:440–8.
31. Verpoort KN, van Gaalen FA, van der Helm-van Mil AH,
Schreuder GM, Breedveld FC, Huizinga TW, et al. Association
of HLA–DR3 with anti–cyclic citrullinated peptide antibody–
negative rheumatoid arthritis. Arthritis Rheum 2005;52:3058–62.
32. Lee HS, Lee AT, Criswell LA, Seldin MF, Amos CI, Carulli JP, et
al. Several regions in the major histocompatibility complex confer
risk for anti-CCP-antibody positive rheumatoid arthritis, indepen-
dent of the DRB1 locus. Mol Med 2008;14:293–300.
33. Li H, Zou Q, Xie Z, Liu Y, Zhong B, Yang S, et al. A haplotype
in STAT4 gene associated with rheumatoid arthritis in Caucasians
is not associated in the Han Chinese population, but with the
presence of rheumatoid factor. Rheumatology (Oxford) 2009;48:
1363–8.
34. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of
patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.
35. Van der Woude D, Lie BA, Lundstrom E, Balsa A, Feitsma AL,
Houwing-Duistermaat JJ, et al. Protection against anti–
citrullinated protein antibody–positive rheumatoid arthritis is pre-
dominantly associated with HLA–DRB1*1301: a meta-analysis
of HLA–DRB1 associations with anti–citrullinated protein
antibody–positive and anti–citrullinated protein antibody–negative
rheumatoid arthritis in four European populations. Arthritis
Rheum 2010;62:1236–45.
36. Skinningsrud B, Lie BA, Husebye ES, Kvien TK, Forre O, Flato B,
et al. A CLEC16A variant confers risk for juvenile idiopathic
arthritis and anti-cyclic citrullinated peptide antibody negative
rheumatoid arthritis. Ann Rheum Dis 2010;69:1471–4.
37. Ates A, Karaaslan Y, Karatayli E, Ertugrul E, Aksaray S, Turky-
ilmaz A, et al. Association of the PTPN22 gene polymorphism with
autoantibody positivity in Turkish rheumatoid arthritis patients.
Tissue Antigens 2011;78:56–9.
38. Montes A, Dieguez-Gonzalez R, Perez-Pampin E, Calaza M,
Mera-Varela A, Gomez-Reino JJ, et al. Particular association of
clinical and genetic features with autoimmunity to citrullinated
-enolase in rheumatoid arthritis. Arthritis Rheum 2011;63:
654–61.
39. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA,
et al. Fibroblast-like synoviocytes of mesenchymal origin express
functional B cell-activating factor of the TNF family in response to
proinflammatory cytokines. J Immunol 2005;174:864–70.
40. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann
GR, et al. Local production of B lymphocyte stimulator protein
and APRIL in arthritic joints of patients with inflammatory
arthritis. Arthritis Rheum 2003;48:982–92.
41. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al.
Importance of cellular microenvironment and circulatory dynam-
ics in B cell immunotherapy. J Immunol 2005;174:817–26.
42. Quartuccio L, Fabris M, Moretti M, Barone F, Bombardieri M,
Rupolo M, et al. Resistance to rituximab therapy and local BAFF
overexpression in Sjo¨gren’s syndrome-related myoepithelial
sialadenitis and low-grade parotid B-cell lymphoma. Open Rheu-
matol J 2008;2:38–43.
43. Youinou P, Pers JO. The late news on BAFF in autoimmune
diseases. Autoimmun Rev 2010;9:804–6.
44. Le Pottier L, Bendaoud B, Renaudineau Y, Youinou P, Pers JO,
Daridon C. New ELISA for B cell-activating factor. Clin Chem
2009;55:1843–51.
BLyS GENOTYPING AND RESPONSE TO RTX IN RA 97
